HK1024866A1 - Protein stabilized pharmacologically active agents and their use - Google Patents

Protein stabilized pharmacologically active agents and their use

Info

Publication number
HK1024866A1
HK1024866A1 HK00103153.7A HK00103153A HK1024866A1 HK 1024866 A1 HK1024866 A1 HK 1024866A1 HK 00103153 A HK00103153 A HK 00103153A HK 1024866 A1 HK1024866 A1 HK 1024866A1
Authority
HK
Hong Kong
Prior art keywords
pharmacologically active
protein
active agents
absence
active agent
Prior art date
Application number
HK00103153.7A
Other languages
English (en)
Inventor
Leslie Louie
Neil P Desai
Patrick Soon-Shiong
Chunlin Tao
Tiantli Zheng
Andrew Yang
Shlomo Magdassi
Zhiwen Yao
Original Assignee
Abraxis Bioscience Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24895164&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK1024866(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abraxis Bioscience Llc filed Critical Abraxis Bioscience Llc
Publication of HK1024866A1 publication Critical patent/HK1024866A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/906—Drug delivery
    • Y10S977/907—Liposome
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/915—Therapeutic or pharmaceutical composition
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S977/00—Nanotechnology
    • Y10S977/902—Specified use of nanostructure
    • Y10S977/904—Specified use of nanostructure for medical, immunological, body treatment, or diagnosis
    • Y10S977/927—Diagnostic contrast agent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Medical Informatics (AREA)
  • Polymers & Plastics (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Molecular Biology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Pediatric Medicine (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Biophysics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
HK00103153.7A 1996-10-01 2000-05-27 Protein stabilized pharmacologically active agents and their use HK1024866A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/720,756 US5916596A (en) 1993-02-22 1996-10-01 Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
PCT/US1997/017157 WO1998014174A1 (fr) 1996-10-01 1997-09-24 Agents pharmaceutiquement actifs stabilises par proteine, procedes de preparation et procedes d'utilisation

Publications (1)

Publication Number Publication Date
HK1024866A1 true HK1024866A1 (en) 2000-10-27

Family

ID=24895164

Family Applications (1)

Application Number Title Priority Date Filing Date
HK00103153.7A HK1024866A1 (en) 1996-10-01 2000-05-27 Protein stabilized pharmacologically active agents and their use

Country Status (19)

Country Link
US (1) US5916596A (fr)
EP (3) EP2286798A1 (fr)
JP (2) JP4837809B2 (fr)
CN (2) CN1515244B (fr)
AT (1) ATE427739T1 (fr)
AU (1) AU718753B2 (fr)
BR (2) BRPI9715297B8 (fr)
CA (2) CA2512487C (fr)
DE (2) DE122009000065I1 (fr)
DK (1) DK0961612T4 (fr)
ES (2) ES2609853T3 (fr)
FR (1) FR09C0050I2 (fr)
HK (1) HK1024866A1 (fr)
LU (1) LU91613I2 (fr)
NL (1) NL300417I1 (fr)
NO (1) NO328689B1 (fr)
NZ (1) NZ335133A (fr)
PT (1) PT961612E (fr)
WO (1) WO1998014174A1 (fr)

Families Citing this family (325)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030133955A1 (en) * 1993-02-22 2003-07-17 American Bioscience, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US6537579B1 (en) * 1993-02-22 2003-03-25 American Bioscience, Inc. Compositions and methods for administration of pharmacologically active compounds
US20070117863A1 (en) * 1993-02-22 2007-05-24 Desai Neil P Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US6749868B1 (en) * 1993-02-22 2004-06-15 American Bioscience, Inc. Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof
US6096331A (en) 1993-02-22 2000-08-01 Vivorx Pharmaceuticals, Inc. Methods and compositions useful for administration of chemotherapeutic agents
US20030068362A1 (en) * 1993-02-22 2003-04-10 American Bioscience, Inc. Methods and formulations for the delivery of pharmacologically active agents
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US6753006B1 (en) 1993-02-22 2004-06-22 American Bioscience, Inc. Paclitaxel-containing formulations
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US6774278B1 (en) 1995-06-07 2004-08-10 Cook Incorporated Coated implantable medical device
US6143211A (en) * 1995-07-21 2000-11-07 Brown University Foundation Process for preparing microparticles through phase inversion phenomena
US20070092563A1 (en) * 1996-10-01 2007-04-26 Abraxis Bioscience, Inc. Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
US20030203036A1 (en) 2000-03-17 2003-10-30 Gordon Marc S. Systems and processes for spray drying hydrophobic drugs with hydrophilic excipients
GB9703673D0 (en) * 1997-02-21 1997-04-09 Bradford Particle Design Ltd Method and apparatus for the formation of particles
HU230338B1 (hu) * 1997-06-27 2016-02-29 Abraxis Bioscience Llc Gyógyászati hatóanyagokat tartalmazó új készítmények, eljárás ilyen készítmények előállítására és alkalmazására
US20030199425A1 (en) * 1997-06-27 2003-10-23 Desai Neil P. Compositions and methods for treatment of hyperplasia
KR101180181B1 (ko) * 1997-06-27 2012-09-05 아브락시스 바이오사이언스, 엘엘씨 나노 입자 및 그의 제조 방법
US8853260B2 (en) * 1997-06-27 2014-10-07 Abraxis Bioscience, Llc Formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
DE69841984D1 (de) * 1997-09-05 2010-12-16 Maruho K K Zusammensetzung aus nanokapseln zur behandlung von intraarticulaeren erkrankungen
HUP9701554D0 (en) * 1997-09-18 1997-11-28 Human Oltoanyagtermeloe Gyogys Pharmaceutical composition containing plazma proteins
US6884842B2 (en) 1997-10-14 2005-04-26 Alnis Biosciences, Inc. Molecular compounds having complementary surfaces to targets
US20030059465A1 (en) * 1998-05-11 2003-03-27 Unger Evan C. Stabilized nanoparticle formulations of camptotheca derivatives
EP1100494A1 (fr) * 1998-07-30 2001-05-23 Novopharm Biotech, Inc. Composition pharmaceutiquement acceptable comprenant une solution aqueuse de paclitaxel et d'albumine
GB9820746D0 (en) † 1998-09-23 1998-11-18 Pharmax Limited Micronised pharmaceutical compositions
US8293277B2 (en) * 1998-10-01 2012-10-23 Alkermes Pharma Ireland Limited Controlled-release nanoparticulate compositions
US8236352B2 (en) * 1998-10-01 2012-08-07 Alkermes Pharma Ireland Limited Glipizide compositions
US20040013613A1 (en) * 2001-05-18 2004-01-22 Jain Rajeev A Rapidly disintegrating solid oral dosage form
CA2346001C (fr) * 1998-10-01 2003-12-30 Elan Pharma International, Limited Liberation regulee de compositions nanoparticulaires
AT406054B (de) * 1998-11-04 2000-02-25 Andreas Bernkop-Schnuerch Verfahren zur verbesserung der mucoadhäsion von polymeren sowie deren herstellung und verwendung
US6428814B1 (en) * 1999-10-08 2002-08-06 Elan Pharma International Ltd. Bioadhesive nanoparticulate compositions having cationic surface stabilizers
US7521068B2 (en) * 1998-11-12 2009-04-21 Elan Pharma International Ltd. Dry powder aerosols of nanoparticulate drugs
US7459283B2 (en) * 2002-02-04 2008-12-02 Elan Pharma International Limited Nanoparticulate compositions having lysozyme as a surface stabilizer
US20040141925A1 (en) * 1998-11-12 2004-07-22 Elan Pharma International Ltd. Novel triamcinolone compositions
DE19856432A1 (de) * 1998-12-08 2000-06-15 Basf Ag Nanopartikuläre Kern-Schale Systeme sowie deren Verwendung in pharmazeutischen und kosmetischen Zubereitungen
DE19919769A1 (de) 1999-04-30 2000-11-02 Henkel Kgaa Verwendung nanoskaliger antimikrobieller Wirkstoffe in Körperdeodorantien
GB9910975D0 (en) * 1999-05-13 1999-07-14 Univ Strathclyde Rapid dehydration of proteins
CA2684454A1 (fr) * 1999-05-21 2000-11-18 American Bioscience, Llc. Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
US6610317B2 (en) 1999-05-27 2003-08-26 Acusphere, Inc. Porous paclitaxel matrices and methods of manufacture thereof
US7919119B2 (en) * 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
GB2350297A (en) * 1999-05-27 2000-11-29 Abbott Lab Injectable halogenated anesthetic formulation in emulsion form
US20090104273A1 (en) * 1999-06-22 2009-04-23 Elan Pharma International Ltd. Novel nifedipine compositions
US20040115134A1 (en) * 1999-06-22 2004-06-17 Elan Pharma International Ltd. Novel nifedipine compositions
DE19932157A1 (de) * 1999-07-13 2001-01-18 Pharmasol Gmbh Verfahren zur schonenden Herstellung von hochfeinen Mikropartikeln und Nanopartikeln
US6656504B1 (en) 1999-09-09 2003-12-02 Elan Pharma International Ltd. Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions
ES2337017T3 (es) * 1999-10-13 2010-04-20 Novartis Vaccines And Diagnostics, Inc. Procedimiento para obtener respuestas inmunitarias celulares de proteinas.
US20040009229A1 (en) * 2000-01-05 2004-01-15 Unger Evan Charles Stabilized nanoparticle formulations of camptotheca derivatives
JP2003520210A (ja) * 2000-01-05 2003-07-02 イマレックス セラピューティクス， インコーポレイテッド 低い水溶性を有する薬物の送達のための薬学的処方物
US20020041898A1 (en) * 2000-01-05 2002-04-11 Unger Evan C. Novel targeted delivery systems for bioactive agents
GB2359747B (en) * 2000-02-29 2002-04-24 Maelor Pharmaceuticals Ltd Anaesthetic formulations
ES2327901T3 (es) * 2000-03-23 2009-11-05 Basf Catalysts Llc Metodo para preparar dispersiones que contienen ingredientes fisiologicamente activos a alta presion/alta cizalla.
ITMI20001107A1 (it) * 2000-05-18 2001-11-18 Acs Dobfar Spa Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel
US20040156872A1 (en) * 2000-05-18 2004-08-12 Elan Pharma International Ltd. Novel nimesulide compositions
DE10036871A1 (de) * 2000-07-28 2002-02-14 Pharmasol Gmbh Dispersionen zur Formulierung wenig oder schwer löslicher Wirkstoffe
US6623765B1 (en) 2000-08-01 2003-09-23 University Of Florida, Research Foundation, Incorporated Microemulsion and micelle systems for solubilizing drugs
US7198795B2 (en) 2000-09-21 2007-04-03 Elan Pharma International Ltd. In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions
CA2423484A1 (fr) 2000-09-27 2002-04-04 Verion Inc. Capsule soluble dans l'eau instantanement et procede
AU2001296480A1 (en) * 2000-10-02 2002-04-15 Kimberly-Clark Worldwide, Inc. Recording medium with nanoparticles and methods of making the same
US7803149B2 (en) * 2002-07-12 2010-09-28 Cook Incorporated Coated medical device
CA2427467C (fr) 2000-11-09 2010-01-12 Neopharm, Inc. Complexes lipidiques a base de sn-38 et procedes d'utilisation
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
US6607784B2 (en) * 2000-12-22 2003-08-19 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US9700866B2 (en) * 2000-12-22 2017-07-11 Baxter International Inc. Surfactant systems for delivery of organic compounds
US6951656B2 (en) * 2000-12-22 2005-10-04 Baxter International Inc. Microprecipitation method for preparing submicron suspensions
US20050048126A1 (en) * 2000-12-22 2005-03-03 Barrett Rabinow Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug
US20040256749A1 (en) * 2000-12-22 2004-12-23 Mahesh Chaubal Process for production of essentially solvent-free small particles
US6884436B2 (en) * 2000-12-22 2005-04-26 Baxter International Inc. Method for preparing submicron particle suspensions
US8067032B2 (en) 2000-12-22 2011-11-29 Baxter International Inc. Method for preparing submicron particles of antineoplastic agents
US20030096013A1 (en) * 2000-12-22 2003-05-22 Jane Werling Preparation of submicron sized particles with polymorph control
US6977085B2 (en) * 2000-12-22 2005-12-20 Baxter International Inc. Method for preparing submicron suspensions with polymorph control
US7193084B2 (en) * 2000-12-22 2007-03-20 Baxter International Inc. Polymorphic form of itraconazole
US7115565B2 (en) 2001-01-18 2006-10-03 Pharmacia & Upjohn Company Chemotherapeutic microemulsion compositions of paclitaxel with improved oral bioavailability
US20040022861A1 (en) * 2001-01-30 2004-02-05 Williams Robert O. Process for production of nanoparticles and microparticles by spray freezing into liquid
US20030157170A1 (en) * 2001-03-13 2003-08-21 Richard Liggins Micellar drug delivery vehicles and precursors thereto and uses thereof
WO2002072150A2 (fr) * 2001-03-13 2002-09-19 Angiotech Pharmaceuticals Inc. Vecteurs de delivrance de medicament micellaires, leurs precurseurs et leurs utilisations
DE10115740A1 (de) 2001-03-26 2002-10-02 Ulrich Speck Zubereitung für die Restenoseprophylaxe
AU2002245979A1 (en) * 2001-04-05 2002-10-21 Universite Laval Process for making protein delivery matrix and uses thereof
ATE363898T1 (de) * 2001-04-20 2007-06-15 Univ British Columbia Mizellares arzneistoffverabreichungssystem für hydrophobe arzneistoffe
SG126676A1 (en) * 2001-05-09 2007-01-30 Nanomaterials Tech Pte Ltd Process for the controlled production of organic particles
WO2003030864A1 (fr) * 2001-05-29 2003-04-17 Neopharm, Inc. Formulation liposomale d'irinotecan
CA2451187C (fr) 2001-06-22 2012-08-14 Southern Biosystems, Inc. Implants coaxiaux a liberation prolongee d'ordre 0
GB0116074D0 (en) * 2001-06-29 2001-08-22 Univ Strathclyde Nanoparticle structures
US20040013698A1 (en) * 2001-07-09 2004-01-22 Aust Duncan T Method for preparing topical preparations containing skin protective agents with enhanced barrier properties
TWI332943B (en) * 2001-07-10 2010-11-11 Synta Pharmaceuticals Corp Taxol enhancer compounds
TWI252847B (en) * 2001-07-10 2006-04-11 Synta Pharmaceuticals Corp Synthesis of taxol enhancers
TWI297335B (en) 2001-07-10 2008-06-01 Synta Pharmaceuticals Corp Taxol enhancer compounds
US20040018250A1 (en) * 2001-07-11 2004-01-29 Ceccoli Joseph D. Methods for preparing high pressure/high shear dispersions containing waxes and other semi-solids and oils
EP1423175B1 (fr) * 2001-08-08 2013-10-02 Brown University Research Foundation Procedes de micronisation de medicaments hydrophobes
US20030199587A1 (en) * 2001-08-14 2003-10-23 Franz G. Andrew Levothyroxine compositions having unique Cmax properties
US20030054042A1 (en) * 2001-09-14 2003-03-20 Elaine Liversidge Stabilization of chemical compounds using nanoparticulate formulations
EP1429749A2 (fr) * 2001-09-26 2004-06-23 Baxter International Inc. Preparation de nanoparticules submicroniques par dispersion et elimination d'un solvant ou d'une phase liquide
US20060003012A9 (en) 2001-09-26 2006-01-05 Sean Brynjelsen Preparation of submicron solid particle suspensions by sonication of multiphase systems
US20040015519A1 (en) * 2001-10-15 2004-01-22 Yukitoshi Maeda Content delivery server and content delivery system having the same
CA2461556A1 (fr) * 2001-10-15 2003-04-24 Crititech, Inc. Compositions et procedes destines a l'administration de microparticules de medicaments faiblement hydrosolubles et procedes de traitement associes
US7112340B2 (en) * 2001-10-19 2006-09-26 Baxter International Inc. Compositions of and method for preparing stable particles in a frozen aqueous matrix
ATE425178T1 (de) 2001-10-19 2009-03-15 Isotechnika Inc Synthese von cyclosporinanalogen
WO2003037359A1 (fr) * 2001-10-29 2003-05-08 Chengdu Somo Namotechnology Co., Ltd. Nanoparticule de composants de medicaments insolubles et procede de production correspondant
US20040101566A1 (en) * 2002-02-04 2004-05-27 Elan Pharma International Limited Novel benzoyl peroxide compositions
US20080220075A1 (en) * 2002-03-20 2008-09-11 Elan Pharma International Ltd. Nanoparticulate compositions of angiogenesis inhibitors
WO2003080027A1 (fr) * 2002-03-20 2003-10-02 Elan Pharma International, Ltd. Compositions nanoparticulaires d'inhibiteurs d'angiogenese
WO2003082213A2 (fr) * 2002-03-28 2003-10-09 Imcor Pharmaceutical Company Compositions et procedes de distribution d'agents pharmaceutiquement actifs au moyen de nanoparticules
ITMI20020681A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Procedimento per la produzione di nanoparticelle di paclitaxel ed albumina
ITMI20020680A1 (it) * 2002-03-29 2003-09-29 Acs Dobfar Spa Composizione antitumorale migliorata a base di paclitaxel e metodo per il suo ottenimento
US20040082521A1 (en) * 2002-03-29 2004-04-29 Azaya Therapeutics Inc. Novel formulations of digitalis glycosides for treating cell-proliferative and other diseases
US8501232B2 (en) * 2002-04-23 2013-08-06 Nanotherapeutics, Inc. Process of forming and modifying particles and compositions produced thereby
GB0216562D0 (en) 2002-04-25 2002-08-28 Bradford Particle Design Ltd Particulate materials
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
KR101003514B1 (ko) * 2002-07-15 2010-12-30 알콘, 인코퍼레이티드 안용 약물 전달을 위한 생침식성 필름
AU2003261167A1 (en) * 2002-07-16 2004-02-02 Elan Pharma International, Ltd Liquid dosage compositions of stable nanoparticulate active agents
GB0216700D0 (en) 2002-07-18 2002-08-28 Astrazeneca Ab Process
DE10234165B4 (de) * 2002-07-26 2008-01-03 Advanced Micro Devices, Inc., Sunnyvale Verfahren zum Füllen eines Grabens, der in einem Substrat gebildet ist, mit einem isolierenden Material
EP1530457B1 (fr) 2002-08-12 2009-09-09 Bend Research, Inc. Compositions pharmaceutiques de medicaments à structure semi-ordonnée et de polymères
WO2004035032A2 (fr) * 2002-08-20 2004-04-29 Neopharm, Inc. Formulation de sn-38 a base de lipides pharmaceutiquement actifs
US20060030578A1 (en) * 2002-08-20 2006-02-09 Neopharm, Inc. Pharmaceutically active lipid based formulation of irinotecan
US7090868B2 (en) * 2002-09-13 2006-08-15 University Of Florida Materials and methods for drug delivery and uptake
DE10244847A1 (de) * 2002-09-20 2004-04-01 Ulrich Prof. Dr. Speck Medizinische Vorrichtung zur Arzneimittelabgabe
US20050051922A1 (en) * 2002-09-20 2005-03-10 Avinash Nangia Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
WO2004032947A1 (fr) * 2002-10-09 2004-04-22 Unibioscreen S.A. Extrait ayant un action antitumoral et antitoxique
KR20050083853A (ko) * 2002-10-28 2005-08-26 폴리머릭스 코포레이션 치료 조성물
WO2004098570A1 (fr) * 2002-10-30 2004-11-18 Spherics, Inc. Agents bioactifs nanoparticulaires
AU2003287526A1 (en) * 2002-11-06 2004-06-03 Protein-stabilized liposomal formulations of pharmaceutical agents
GB2410687A (en) * 2002-11-20 2005-08-10 Univ Bar Ilan Biological glue based on thrombin-conjugated nanoparticles
KR20110079741A (ko) * 2002-12-09 2011-07-07 아브락시스 바이오사이언스, 엘엘씨 약리학적 물질의 조성물 및 그 전달방법
RU2361615C2 (ru) * 2002-12-09 2009-07-20 Абраксис Байосайенс, Ллс. Композиции и способы доставки фармакологических агентов
AU2003299590B8 (en) 2002-12-09 2010-04-08 Abraxis Bioscience, Llc Compositions and methods of delivery of pharmacological agents
US8409618B2 (en) 2002-12-20 2013-04-02 Kimberly-Clark Worldwide, Inc. Odor-reducing quinone compounds
US6780896B2 (en) * 2002-12-20 2004-08-24 Kimberly-Clark Worldwide, Inc. Stabilized photoinitiators and applications thereof
US7666410B2 (en) 2002-12-20 2010-02-23 Kimberly-Clark Worldwide, Inc. Delivery system for functional compounds
TWI330079B (en) * 2003-01-15 2010-09-11 Synta Pharmaceuticals Corp Treatment for cancers
DE60311958T2 (de) * 2003-02-03 2007-11-08 Polaschegg, Hans-Dietrich, Dr. Zusammensetzung zur Prävention von Infektionen durch subkutane Prothesen
GB0302673D0 (en) 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
US7968115B2 (en) 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
WO2004080396A2 (fr) * 2003-03-07 2004-09-23 The University Of Texas Md Anderson Cancer Center Curcumine liposomale pour traiter le cancer
US20040225022A1 (en) * 2003-05-09 2004-11-11 Desai Neil P. Propofol formulation containing reduced oil and surfactants
US20040247624A1 (en) * 2003-06-05 2004-12-09 Unger Evan Charles Methods of making pharmaceutical formulations for the delivery of drugs having low aqueous solubility
US8476010B2 (en) * 2003-07-10 2013-07-02 App Pharmaceuticals Llc Propofol formulations with non-reactive container closures
US20050181018A1 (en) * 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US20070196914A1 (en) * 2003-10-02 2007-08-23 Sembiosys Genetics Inc. Methods for preparing oil bodies comprising active ingredients
US7678367B2 (en) 2003-10-16 2010-03-16 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified particles
US7879350B2 (en) * 2003-10-16 2011-02-01 Kimberly-Clark Worldwide, Inc. Method for reducing odor using colloidal nanoparticles
US7754197B2 (en) 2003-10-16 2010-07-13 Kimberly-Clark Worldwide, Inc. Method for reducing odor using coordinated polydentate compounds
US7438875B2 (en) * 2003-10-16 2008-10-21 Kimberly-Clark Worldwide, Inc. Method for reducing odor using metal-modified silica particles
US7837663B2 (en) * 2003-10-16 2010-11-23 Kimberly-Clark Worldwide, Inc. Odor controlling article including a visual indicating device for monitoring odor absorption
US7488520B2 (en) 2003-10-16 2009-02-10 Kimberly-Clark Worldwide, Inc. High surface area material blends for odor reduction, articles utilizing such blends and methods of using same
US7794737B2 (en) 2003-10-16 2010-09-14 Kimberly-Clark Worldwide, Inc. Odor absorbing extrudates
US7413550B2 (en) 2003-10-16 2008-08-19 Kimberly-Clark Worldwide, Inc. Visual indicating device for bad breath
EP1704135A4 (fr) * 2003-12-23 2007-10-24 Abraxis Bioscience Inc Analogues du propofol, procede permettant de les preparer et methodes permettant de les utiliser
WO2005062985A2 (fr) * 2003-12-23 2005-07-14 American Bioscience, Inc. Promedicaments diester a base de camptothecine, leur procede de preparation et leurs applications therapeutiques
CA2551117A1 (fr) * 2003-12-23 2005-07-14 Abraxis Bioscience, Inc. Derives substitues de melatonine, procede de fabrication et methodes d'utilisation
US20050186230A1 (en) * 2004-01-23 2005-08-25 Sd Pharmaceuticals, Inc. Elemene compositions containing liquid oil
EP1713514B1 (fr) * 2004-01-28 2021-11-24 Johns Hopkins University Medicaments et particules de transport de genes se depla ant rapidement a travers les barrieres muqueuses
WO2005077337A2 (fr) * 2004-02-05 2005-08-25 Baxter International Inc. Dispersions preparees avec des agents autostabilisants
US20080103213A1 (en) * 2004-03-05 2008-05-01 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of neurofibromatosis
US8784881B2 (en) 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
MXPA06011972A (es) * 2004-04-13 2007-04-16 Johnson & Johnson Aparato y metodo para el suministro transdermico de agentes a base de fentanilo.
CA2469339A1 (fr) * 2004-06-07 2005-12-07 Bernard Charles Sherman Gelules a liberation lente de chlorhydrate de propafenone
BRPI0512526A (pt) 2004-06-23 2008-03-11 Synta Pharmaceuticals Corp composto, composição farmacêutica, método para tratar um paciente com cáncer e método para preparar um di-sal de bis(tio-hidrazida amida)
JP4433918B2 (ja) * 2004-07-15 2010-03-17 コニカミノルタエムジー株式会社 画像形成方法
KR100578382B1 (ko) 2004-07-16 2006-05-11 나재운 항암제의 전달체용 수용성 키토산 나노입자 및 그 제조방법
KR100651728B1 (ko) * 2004-11-10 2006-12-06 한국전자통신연구원 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법
US20060198891A1 (en) * 2004-11-29 2006-09-07 Francois Ravenelle Solid formulations of liquid biologically active agents
WO2006066063A1 (fr) * 2004-12-15 2006-06-22 Elan Pharma International Ltd. Formulations renfermant des nanoparticules de tacrolimus
WO2006089120A2 (fr) 2005-02-18 2006-08-24 Abraxis Bioscience, Inc Compositions, procedes d'utilisation et de preparation de 2,6-diisopropylphenol et d'analogues de ce dernier pour traiter une liaison ischemique
US20070166388A1 (en) 2005-02-18 2007-07-19 Desai Neil P Combinations and modes of administration of therapeutic agents and combination therapy
US8735394B2 (en) 2005-02-18 2014-05-27 Abraxis Bioscience, Llc Combinations and modes of administration of therapeutic agents and combination therapy
PL3248600T3 (pl) * 2005-02-18 2020-09-07 Abraxis Bioscience, Llc Połączenia i sposoby podawania środków terapeutycznych i terapia skojarzona
US8415388B2 (en) 2005-02-22 2013-04-09 Savvipharm Inc. Pharmaceutical compositions containing paclitaxel orotate
AU2006227623B2 (en) * 2005-03-17 2011-10-20 Elan Pharma International Limited Injectable compositions of nanoparticulate immunosuppressive compounds
US20060229585A1 (en) * 2005-04-11 2006-10-12 Minu, L.L.C. Drug delivery to the crystalline lens and other ocular structures
US7722581B2 (en) * 2005-04-11 2010-05-25 Gholam A. Peyman Crystalline lens drug delivery
AU2006235487B2 (en) 2005-04-12 2011-12-22 Elan Pharma International Limited Nanoparticulate quinazoline derivative formulations
CA2604907A1 (fr) * 2005-04-15 2006-10-26 Synta Pharmaceuticals Corp. Polytherapie anticancereuse avec des composes bis(thiohydrazide) amide
CA2608930A1 (fr) * 2005-06-14 2006-12-28 Baxter International Inc. Preparations pharmaceutiques permettant de reduire les interactions entre medicaments
US20060280787A1 (en) * 2005-06-14 2006-12-14 Baxter International Inc. Pharmaceutical formulation of the tubulin inhibitor indibulin for oral administration with improved pharmacokinetic properties, and process for the manufacture thereof
BRPI0615265A8 (pt) * 2005-08-31 2018-03-06 Abraxis Bioscience Llc composições compreendendo agentes farmacêuticos pouco hidrossoluíveis e agentes antimicrobianos
JP5368093B2 (ja) 2005-08-31 2013-12-18 アブラクシス バイオサイエンス， エルエルシー 増大した安定性を有する難水溶性薬剤の組成物および調製の方法
WO2007029898A1 (fr) * 2005-09-09 2007-03-15 Jae-Woon Nah Nanoparticule de chitosan soluble dans l'eau pour administrer un agent anticancereux et son procede de preparation
US20070098802A1 (en) * 2005-10-31 2007-05-03 Isaac Farr Organic nanoparticles and associated methods
US7942867B2 (en) * 2005-11-09 2011-05-17 The Invention Science Fund I, Llc Remotely controlled substance delivery device
EP1954252B1 (fr) * 2005-12-02 2016-02-03 GlaxoSmithKline Biologicals SA Nanoparticules destinees a etre utilisees dans des compositions immunogenes
DE102005062440B4 (de) * 2005-12-27 2011-02-24 Lts Lohmann Therapie-Systeme Ag Proteinbasiertes Trägersystem zur Resistenzüberwindung von Tumorzellen
AU2006329554C1 (en) 2005-12-28 2013-06-20 Fresenius Kabi Oncology Limited A biocompatible, non-biodegradable, non-toxic polymer useful for nanoparticle pharmaceutical compositions
SE529040C2 (sv) 2006-01-18 2007-04-17 Bows Pharmaceuticals Ag Förfarande för framställning av en dextranmatris för kontrollerad frisättning av insulin
AR054215A1 (es) 2006-01-20 2007-06-13 Eriochem Sa Una formulacion farmaceutica de un taxano, una composicion solida de un taxano liofilizado a partir de una solucion de acido acetico, un procedimiento para la preparacion de dicha composicion solida de un taxano, una composicion solubilizante de un taxano liofilizado, y un conjunto de elementos (kit
JP4974533B2 (ja) * 2006-01-30 2012-07-11 富士フイルム株式会社 ジスルフィド架橋したタンパク質ナノ粒子
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US7458953B2 (en) * 2006-06-20 2008-12-02 Gholam A. Peyman Ocular drainage device
WO2008013785A2 (fr) * 2006-07-24 2008-01-31 Singh-Broemer And Company, Inc. Formulation de nanoparticules solides de substances pharmaceutiques insolubles dans l'eau avec mûrissement d'ostwald réduit
NZ575350A (en) 2006-08-21 2012-02-24 Synta Pharmaceuticals Corp Bis(phenylcarbonothioyl)hydrazide derivatives
US20080280987A1 (en) * 2006-08-31 2008-11-13 Desai Neil P Methods of inhibiting angiogenesis and treating angiogenesis-associated diseases
AU2007290490B2 (en) * 2006-08-31 2011-09-08 Synta Pharmaceuticals Corp. Combination with bis(thiohydrazide amides) for treating cancer
CA2663003C (fr) * 2006-09-08 2018-02-13 Justin Hanes Compositions et methodes destinees a ameliorer le transport a travers le mucus
US9498528B2 (en) * 2006-09-13 2016-11-22 Genzyme Corporation Treatment of multiple sclerosis (MS)
US20110021592A1 (en) * 2006-09-14 2011-01-27 Shlomo Magdassi Organic nanoparticles obtained from microemulsions by solvent evaporation
AR063704A1 (es) 2006-09-14 2009-02-11 Makhteshim Chem Works Ltd Nanoparticulas de pesticida obtenida obtenidas a partir de microemulsiones y nanoemulsiones
WO2008036858A2 (fr) 2006-09-20 2008-03-27 The Board Of Regents Of The University Of Texas System procédé pour administrer des anesthésiants volatils pour une anesthésie locale et/ou le soulagement de la douleur
JP5099545B2 (ja) * 2006-10-17 2012-12-19 公立大学法人大阪府立大学 化合物の溶解補助剤とそれを含む組成物
PL2091919T3 (pl) * 2006-11-15 2011-12-30 Abraxis Bioscience Llc Pochodne analogów hydrokwinonu geldanamycyny podstawionych 18-amino, o aktywności cytotoksycznej do leczenia raka
US7799954B2 (en) * 2006-11-17 2010-09-21 Abraxis Bioscience, Llc Dicarbonyl derivatives and methods of use
ES2700074T3 (es) 2006-12-14 2019-02-13 Abraxis Bioscience Llc Terapia para el cáncer de mama sobre la base del estado de los receptores hormonales con nanopartículas que comprenden taxano
EP2425840B1 (fr) 2006-12-15 2015-04-08 Abraxis BioScience, Inc. Dérivés de triazine et leurs applications thérapeutiques
PL2481402T3 (pl) 2007-03-07 2018-11-30 Abraxis Bioscience, Llc Nanocząstka zawierająca rapamycynę i albuminę jako środek przeciwnowotworowy
WO2008137148A2 (fr) 2007-05-03 2008-11-13 Abraxis Bioscience, Llc Procédés et compositions permettant le traitement de l'hypertension pulmonaire
US8722736B2 (en) 2007-05-22 2014-05-13 Baxter International Inc. Multi-dose concentrate esmolol with benzyl alcohol
US8426467B2 (en) 2007-05-22 2013-04-23 Baxter International Inc. Colored esmolol concentrate
JP5579057B2 (ja) * 2007-06-01 2014-08-27 アブラクシス バイオサイエンス， エルエルシー 再発性癌の処置のための方法および組成物
EP2207570A2 (fr) * 2007-09-14 2010-07-21 Nitto Denko Corporation Vecteurs de médicament
AR063111A1 (es) 2007-10-03 2008-12-30 Eriochem Sa Una formulacion farmaceutica de taxano
US9675544B2 (en) 2008-01-22 2017-06-13 The Board Of Regents Of The University Of Texas System Volatile anesthetic compositions comprising extractive solvents for regional anesthesia and/or pain relief
KR20150136137A (ko) * 2008-04-10 2015-12-04 아브락시스 바이오사이언스, 엘엘씨 소수성 탁산 유도체의 조성물 및 그의 용도
WO2009126401A1 (fr) * 2008-04-10 2009-10-15 Abraxis Bioscience, Llc Compositions de dérivés hydrophobes de taxane et leurs utilisations
WO2009135125A2 (fr) 2008-05-01 2009-11-05 Bayer Schering Pharma Ag Techniques et procédés pour l'adhésion d'un médicament à un ballonnet de cathéter
CN101658516B (zh) * 2008-08-26 2011-10-05 齐鲁制药有限公司 紫杉醇类药物组合物及其制备方法
WO2010068925A1 (fr) 2008-12-11 2010-06-17 Abraxis Bioscience, Llc Combinaisons et modes d'administration d'agents thérapeutiques et thérapie combinatoire
EP2405750B1 (fr) 2009-03-13 2018-05-09 Abraxis BioScience, LLC Polythérapie avec des dérivés de thiocolchicine
US7828996B1 (en) * 2009-03-27 2010-11-09 Abbott Cardiovascular Systems Inc. Method for the manufacture of stable, nano-sized particles
HUE047376T2 (hu) 2009-04-15 2020-04-28 Abraxis Bioscience Llc Prionmentes nanorészecske-készítmények és elõállításuk
CN102573480B (zh) 2009-06-09 2015-06-10 加利福尼亚资本权益有限责任公司 三嗪衍生物及其治疗应用
JP2012529517A (ja) 2009-06-09 2012-11-22 アブラクシス バイオサイエンス リミテッド ライアビリティー カンパニー ベンジル置換トリアジン誘導体類及びそれらの治療応用
BRPI1011247A2 (pt) 2009-06-09 2016-06-21 California Capital Equity Llc derivados de isoquinolina, quinolina e quinazolina como inibidores de sinalização de hedgehog
CN101653611B (zh) * 2009-07-23 2012-05-09 复旦大学 一种白蛋白-阿霉素纳米制剂及其制备方法和应用
WO2011017835A1 (fr) * 2009-08-11 2011-02-17 Nanjing University Procédé de préparation de nanoparticules protéiques ou peptidiques pour l'administration de médicaments in vivo par déploiement et repliement
DK2470173T3 (en) 2009-08-25 2016-06-06 Abraxis Bioscience Llc Combination therapy of nanoparticle composition of the taxane and the hedgehog inhibitors
US10350364B2 (en) 2009-11-11 2019-07-16 Windgap Medical, Inc. Portable Drug Mixing and Delivery Device and Associated Methods
US9211283B2 (en) 2009-12-11 2015-12-15 Biolitec Pharma Marketing Ltd Nanoparticle carrier systems based on human serum albumin for photodynamic therapy
CA2788663C (fr) * 2010-02-03 2018-05-01 Oncbiomune, L.L.C. Compositions contenant un taxane ou un taxoide et une proteine
LT2552438T (lt) 2010-03-26 2016-09-26 Abraxis Bioscience, Llc Hepatoceliulinės karcinomos gydymo būdai
NZ628423A (en) 2010-03-29 2016-03-31 Abraxis Bioscience Llc Methods of treating cancer
KR20130028727A (ko) 2010-03-29 2013-03-19 아브락시스 바이오사이언스, 엘엘씨 치료제의 약물 전달 및 유효성 향상 방법
JP2013525285A (ja) 2010-04-08 2013-06-20 サンフォード−バーナム メディカル リサーチ インスティテュート 化合物の送達を増強するための方法および組成物
RU2621640C2 (ru) 2010-06-02 2017-06-06 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Способы лечения рака мочевого пузыря
SG186112A1 (en) 2010-06-04 2013-01-30 Abraxis Bioscience Llc Methods of treatment of pancreatic cancer
JP6031437B2 (ja) 2010-06-07 2016-11-24 アブラクシス バイオサイエンス， エルエルシー 増殖性疾患を処置するための組み合わせ療法
CN103202812B (zh) * 2010-08-09 2015-10-28 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
CN103202813B (zh) * 2010-08-09 2015-09-30 南京大学 一种制备用于体内递送药理活性物质的蛋白纳米粒的方法
KR101223484B1 (ko) * 2010-10-05 2013-01-17 한국과학기술연구원 사람 혈청 알부민-ｓｉＲＮＡ 나노입자 전달체
US8884027B2 (en) 2010-10-22 2014-11-11 University Of Rochester Melampomagnolide B derivatives as antileukemic and cytotoxic agents
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2012118778A1 (fr) 2011-02-28 2012-09-07 Sanford-Burnham Medical Research Institute Peptides car tronqués, procédés et compositions les utilisant
RU2475247C2 (ru) * 2011-03-05 2013-02-20 Республика Северная Осетия-Алания "Всероссийское общество изобретателей и рационализаторов" ("ВОИР") Способ профилактики несостоятельности кишечного анастомоза
CN102133190A (zh) * 2011-03-16 2011-07-27 中国药科大学 一种转铁蛋白纳米粒及其制备方法和用途
CO6540157A1 (es) 2011-04-15 2012-10-16 Univ Antioquia Proceso continuo para la elaboracion de nanoparticulas y nanoparticulas obtenidas mediante dicho proceso
CN103648521A (zh) 2011-04-28 2014-03-19 阿布拉科斯生物科学有限公司 纳米颗粒组合物的血管内递送及其应用
US10179801B2 (en) 2011-08-26 2019-01-15 Sanford-Burnham Medical Research Institute Truncated LYP-1 peptides and methods and compositions using truncated LYP-1 peptides
US9125884B2 (en) 2011-11-01 2015-09-08 Celgene Corporation Methods for treating cancers using oral formulations of cytidine analogs
WO2013085902A1 (fr) 2011-12-05 2013-06-13 The University Of Texas M.D. Procédés de polythérapie pour le traitement d'un cancer du sein inflammatoire
WO2013084207A1 (fr) 2011-12-07 2013-06-13 Universidade Do Minho Formulations micellaires protéiques et procédé de production correspondant
RU2499991C2 (ru) * 2011-12-14 2013-11-27 Государственное бюджетное образовательное учреждение высшего профессионального образования "Северный государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ дифференциальной диагностики типа гепаторенального синдрома алкогольного генеза
RU2705998C2 (ru) 2011-12-14 2019-11-13 АБРАКСИС БАЙОСАЙЕНС, ЭлЭлСи Применение полимерных эксципиентов для лиофилизации или заморозки частиц
KR102140989B1 (ko) 2012-05-03 2020-08-04 칼라 파마슈티컬스, 인크. 개선된 점막 수송을 나타내는 제약 나노입자
US11596599B2 (en) 2012-05-03 2023-03-07 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
EP3808339A1 (fr) 2012-05-03 2021-04-21 Kala Pharmaceuticals, Inc. Nanoparticles pharmaceutiques montrant du transport mucosale amélioré
US9827191B2 (en) 2012-05-03 2017-11-28 The Johns Hopkins University Compositions and methods for ophthalmic and/or other applications
WO2014018932A2 (fr) 2012-07-27 2014-01-30 Bunt Antonius Martinus Gustave Compositions inhibitrices d'écoulement et méthodes de traitement à l'aide celles-ci
CA2890002A1 (fr) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Derives contenant un sulfonamide cyclique en tant qu'inhibiteurs de la voie de signalisation hedgehog
CA2890018A1 (fr) 2012-11-05 2014-05-08 Nant Holdings Ip, Llc Derives indol-5-ole substitues et leurs applications therapeutiques
US9149455B2 (en) 2012-11-09 2015-10-06 Abraxis Bioscience, Llc Methods of treating melanoma
EP2919903B1 (fr) * 2012-11-14 2020-07-22 W.R. Grace & CO. - CONN. Compositions contenant un matériau biologiquement actif et un oxyde inorganique non ordonné
JP5999765B2 (ja) * 2012-12-07 2016-09-28 バイオアバイラビリティ，インク． 栄養学的に使用するための高濃度自己マイクロエマルジョン化コエンザイムｑ１０調製物
PT106738B (pt) * 2013-01-09 2015-06-08 Hovione Farmaciencia Sa Método para o controlo do fenómeno de degradação difusional de ostwald (ostwald ripening) no processamento de partículas de um ingrediente farmacêutico
US9511046B2 (en) 2013-01-11 2016-12-06 Abraxis Bioscience, Llc Methods of treating pancreatic cancer
CA2900668A1 (fr) 2013-02-11 2014-08-14 Abraxis Bioscience, Llc Traitement du melanome dans lequel est utilise des nanoparticules comprenant du paclitaxel
ITBN20130001A1 (it) * 2013-02-19 2014-08-20 Prodal S C A R L Particelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi in campo alimentare, farmaceutico e cosmetico e procedimento per la loro preparazioneparticelle biopolimeriche sub-micrometriche per la veicolazione di composti attivi
EP2968254B1 (fr) 2013-03-12 2020-04-22 Abraxis BioScience, LLC Procédés de traitement du cancer du poumon
WO2014143613A1 (fr) 2013-03-13 2014-09-18 Abraxis Bioscience, Llc Méthodes de traitement de tumeur solide pédiatrique
KR20150127187A (ko) 2013-03-14 2015-11-16 아브락시스 바이오사이언스, 엘엘씨 방광암의 치료 방법
US9907910B2 (en) 2013-03-15 2018-03-06 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
US9550760B2 (en) 2013-03-15 2017-01-24 Nantbioscience, Inc. Substituted indol-5-ol derivatives and their therapeutic applications
US10391262B2 (en) 2014-03-18 2019-08-27 Windgap Medical, Inc. Removable actuating cap for use with an auto-injector assembly
US10569017B2 (en) 2013-03-15 2020-02-25 Windgap Medical, Inc. Portable drug mixing and delivery device and associated methods
CN110464917A (zh) 2013-03-15 2019-11-19 温德加普医疗股份有限公司 便携式药物混合和递送系统及方法
KR101329646B1 (ko) 2013-05-02 2013-11-14 주식회사 지니스 표적지향증폭형 항암나노입자 및 이의 제조방법
CN103393632B (zh) * 2013-07-26 2015-05-13 齐鲁制药(海南)有限公司 一种卡巴他赛药物组合物及其制备方法
CN104368007A (zh) * 2013-08-12 2015-02-25 于湛 可注射蛋白基花样结构载药微纳材料与内耳跨膜给药缓释制剂及其制备方法
KR20150047336A (ko) 2013-10-24 2015-05-04 삼성전자주식회사 나노입자, 이를 제조하는 방법, 및 이의 용도
CN104758942A (zh) * 2014-01-02 2015-07-08 国家纳米科学中心 基于蛋白质的药理活性物质组合物及其制备方法和应用
CN103705469B (zh) * 2014-01-03 2016-01-20 中国医学科学院药用植物研究所 一种和厚朴酚纳米粒及其制备方法
EP3104901B1 (fr) * 2014-02-14 2020-04-15 Boston Scientific Scimed, Inc. Particules emboliques à dégradation rapide avec libération d'agent thérapeutique
CN103861115B (zh) * 2014-03-18 2017-04-19 常州市第一人民医院 一种血红蛋白纳米粒及其制备方法
US20150359810A1 (en) 2014-06-17 2015-12-17 Celgene Corporation Methods for treating epstein-barr virus (ebv) associated cancers using oral formulations of 5-azacytidine
CN104434808A (zh) 2014-07-03 2015-03-25 石药集团中奇制药技术（石家庄）有限公司 一种治疗性纳米粒子及其制备方法
JP6462859B2 (ja) 2014-08-18 2019-01-30 ウィンドギャップ メディカル， インコーポレイテッド 携帯型薬剤混合及び送達装置並びに関連の方法
US11116903B2 (en) 2014-08-18 2021-09-14 Windgap Medical, Inc Compression seal for use with a liquid component storage vial of an auto-injector
WO2016088384A1 (fr) * 2014-12-05 2016-06-09 国立大学法人神戸大学 Nanoparticule furtive in vivo
CN105727303B (zh) * 2014-12-12 2019-06-28 四川科伦药物研究院有限公司 一种高载卡巴他赛药物的白蛋白组合物及其制剂和制备方法
CN104490797A (zh) * 2014-12-22 2015-04-08 深圳海王药业有限公司 一种多相稳定的白蛋白结合型卡巴他塞
KR20170122782A (ko) 2015-02-27 2017-11-06 난트바이오사이언스 인코포레이티드 키나아제 억제제로서의 피리미딘 유도체 및 그 치료적 용도
US10527604B1 (en) 2015-03-05 2020-01-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and paclitaxel
US10705070B1 (en) 2015-03-05 2020-07-07 Abraxis Bioscience, Llc Methods of assessing suitability of use of pharmaceutical compositions of albumin and poorly water soluble drug
CN106137969B (zh) * 2015-04-03 2020-05-15 四川科伦药物研究院有限公司 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用
US10071141B2 (en) 2015-05-08 2018-09-11 Spectral Platforms, Inc. Albumin-based non-covalent complexes and methods of use thereof
US20160346221A1 (en) 2015-06-01 2016-12-01 Autotelic Llc Phospholipid-coated therapeutic agent nanoparticles and related methods
WO2016210423A2 (fr) 2015-06-25 2016-12-29 Sanford Burnham Prebys Medical Discovery Institute Compositions à administrer dans des plaques athéroscléreuses, pour le traitement de ces plaques
AU2016285720C1 (en) 2015-06-29 2022-02-03 Abraxis Bioscience, Llc Methods of treating epithelioid cell tumors
CN105055341A (zh) * 2015-08-13 2015-11-18 黑龙江泰华源生物技术有限责任公司 一种紫杉醇白蛋白结合型冻干制剂及其制备方法
JP6580777B2 (ja) 2015-08-13 2019-09-25 ウィンドギャップ メディカル， インコーポレイテッド 無菌特徴を有する混合及び注入装置
CN105816885A (zh) * 2016-04-15 2016-08-03 北京大学 一种药物白蛋白纳米粒的制备及其应用方法
BE1023653B1 (nl) * 2016-04-29 2017-06-07 Rousselot B.V. Eiwit gebaseerd excipient voor actieve farmaceutische stoffen
US20190083629A1 (en) * 2016-04-29 2019-03-21 Rousselot B.V. Protein based excipient for active pharmaceutical ingredients
CN105944109B (zh) * 2016-05-03 2019-06-11 四川大学 一种肾小球靶向的蛋白纳米颗粒药物组合物及其用途
CN106310221B (zh) * 2016-08-25 2019-11-22 齐鲁制药有限公司 一种含有卡非佐米的药物组合物及其制备方法
CN109890422A (zh) * 2016-09-06 2019-06-14 梅约医学教育与研究基金会 紫杉醇-白蛋白-结合剂组合物及使用和制备该组合物的方法
MA46474A (fr) * 2016-10-10 2019-08-14 Abraxis Bioscience Llc Formulations nanoparticulaires et leurs procédés de production et d'utilisation
EP3548001B1 (fr) * 2016-11-30 2022-04-13 Dukebox SP. Z O.O. Procédé de fabrication d'une solution de nanoparticules d'acide acétylsalicylique, de diosmine ou de drotavérin
EP3602065A4 (fr) 2017-03-20 2020-12-23 Spectral Platforms, Inc. Procédés de spectroscopie pour détecter et caractériser des micro-organismes
CN110753541A (zh) * 2017-04-24 2020-02-04 Zy治疗公司 用于体内递送的药物组合物、基本上不溶于水的药理学活性剂的制备方法
CN107412783B (zh) * 2017-04-28 2020-09-22 中国人民解放军军事医学科学院毒物药物研究所 一种包裹有难溶于水药物的蛋白质颗粒的制备方法
WO2018204392A1 (fr) 2017-05-02 2018-11-08 Stanford Burnham Prebys Medical Discovery Institute Peptide liant des monocytes/macrophages associés à une tumeur et procédés d'utilisation associés
US10800760B2 (en) 2017-05-31 2020-10-13 Nantbio, Inc. Trk inhibition
US10738033B2 (en) 2017-05-31 2020-08-11 Nantbio, Inc. Trk inhibition
WO2019016692A1 (fr) * 2017-07-21 2019-01-24 Emcure Pharmaceuticals Limited Stabilisation de taille de particule de particules liées à une protéine et procédés associés
CN107412172A (zh) * 2017-08-04 2017-12-01 南京拉克森生物医药科技有限公司 一种紫杉醇白蛋白纳米混悬剂冻干粉及其制备工艺
CN111343971A (zh) * 2017-08-25 2020-06-26 安能泰制药有限公司 药物剂的组合物和递送方法
RU2020118594A (ru) 2017-11-06 2021-12-09 Рапт Терапьютикс, Инк. Противораковые агенты
SG11202009145PA (en) 2018-03-20 2020-10-29 Abraxis Bioscience Llc Methods of treating central nervous system disorders via administration of nanoparticles of an mtor inhibitor and an albumin
CN108524452A (zh) * 2018-05-08 2018-09-14 辽宁大学 一种紫杉醇白蛋白纳米粒的制备方法和应用
CA3100905A1 (fr) 2018-05-22 2019-11-28 Abraxis Bioscience, Llc Methodes et compositions pour le traitement de l'hypertension pulmonaire
WO2020151733A1 (fr) * 2019-01-22 2020-07-30 Novagenesis Therapeutix (Hk) Limited Nanoparticules d'albumine, procédés de production, et appareils associés
US20220119450A1 (en) 2019-02-04 2022-04-21 University Of Tartu Bi-specific extracellular matrix binding peptides and methods of use thereof
WO2020231855A1 (fr) 2019-05-10 2020-11-19 Nant Holdings Ip, Llc Nogapendékine alfa-inbakicept pour thérapies de stimulation immunitaire et traitement d'infections virales
MX2022004989A (es) 2019-10-28 2022-07-21 Abraxis Bioscience Llc Composiciones farmaceuticas de albumina y rapamicina.
US11318189B1 (en) 2020-05-13 2022-05-03 Nantcell, Inc. IL-15 agonist drug combinations for immune therapy
CN114681408B (zh) * 2020-12-26 2023-06-23 四川汇宇制药股份有限公司 白蛋白结合型紫杉醇纳米粒的制备方法
EP4036580A1 (fr) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Agent de cavitation chargé de médicaments
EP4035655A1 (fr) * 2021-02-01 2022-08-03 Oxford University Innovation Limited Articules immunomodulatrices
WO2024081674A1 (fr) 2022-10-11 2024-04-18 Aadi Bioscience, Inc. Polythérapies pour le traitement du cancer

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3959457A (en) * 1970-06-05 1976-05-25 Temple University Microparticulate material and method of making such material
GB1472793A (en) * 1974-03-28 1977-05-04 Ici Ltd Pharmaceutical compositions
US4073943A (en) * 1974-09-11 1978-02-14 Apoteksvarucentralen Vitrum Ab Method of enhancing the administration of pharmalogically active agents
US4247406A (en) * 1979-04-23 1981-01-27 Widder Kenneth J Intravascularly-administrable, magnetically-localizable biodegradable carrier
US4572203A (en) * 1983-01-27 1986-02-25 Feinstein Steven B Contact agents for ultrasonic imaging
US4718433A (en) * 1983-01-27 1988-01-12 Feinstein Steven B Contrast agents for ultrasonic imaging
US4622219A (en) * 1983-06-17 1986-11-11 Haynes Duncan H Method of inducing local anesthesia using microdroplets of a general anesthetic
ATE34407T1 (de) * 1983-06-22 1988-06-15 Stolle Res & Dev Eingekapselte zellen, verfahren zu deren herstellung und ihre verwendung.
US4671954A (en) * 1983-12-13 1987-06-09 University Of Florida Microspheres for incorporation of therapeutic substances and methods of preparation thereof
CA1215922A (fr) * 1984-05-25 1986-12-30 Connaught Laboratories Limited Microencapsulation de cellules et de tissus vivants
US4753788A (en) * 1985-01-31 1988-06-28 Vestar Research Inc. Method for preparing small vesicles using microemulsification
SE459005B (sv) * 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5023271A (en) * 1985-08-13 1991-06-11 California Biotechnology Inc. Pharmaceutical microemulsions
ATE106242T1 (de) * 1986-08-28 1994-06-15 Enzacor Pty Ltd Mikrogranuläre zubereitung zur verabreichung biologisch aktiver stoffe in den eingeweideregionen von tieren.
US4925678A (en) * 1987-04-01 1990-05-15 Ranney David F Endothelial envelopment drug carriers
IE59934B1 (en) * 1987-06-19 1994-05-04 Elan Corp Plc Liquid suspension for oral administration
SE8704158L (sv) * 1987-10-26 1989-04-27 Carbomatrix Ab C O Ulf Schroed Mikrosfaerer, foerfarande foer framstaellning daerav och anvaendning daerav
US4844882A (en) * 1987-12-29 1989-07-04 Molecular Biosystems, Inc. Concentrated stabilized microbubble-type ultrasonic imaging agent
NO176278C (no) * 1988-08-24 1995-03-08 Allied Colloids Ltd Fremgangsmåte for fremstilling av en partikkelformig blanding av aktiv bestanddel i et polymert materiale
US5026559A (en) * 1989-04-03 1991-06-25 Kinaform Technology, Inc. Sustained-release pharmaceutical preparation
DE69005800T2 (de) * 1989-05-01 1994-05-19 Alkermes Inc Verfahren zur herstellung von kleinen partikeln von biologisch aktiven molekülen.
US5019400A (en) * 1989-05-01 1991-05-28 Enzytech, Inc. Very low temperature casting of controlled release microspheres
FR2651680B1 (fr) * 1989-09-14 1991-12-27 Medgenix Group Sa Nouveau procede de preparation de microparticules lipidiques.
FR2660556B1 (fr) * 1990-04-06 1994-09-16 Rhone Poulenc Sante Microspheres, leur procede de preparation et leur utilisation.
EP0524973B1 (fr) * 1990-04-17 1997-01-08 Isp Investments Inc. Preparation de microgouttelettes discretes d'une emulsion aqueuse stabilisee par polymerisation in situ d'un monomere vinylique soluble dans l'eau
US5059699A (en) * 1990-08-28 1991-10-22 Virginia Tech Intellectual Properties, Inc. Water soluble derivatives of taxol
US5110606A (en) * 1990-11-13 1992-05-05 Affinity Biotech, Inc. Non-aqueous microemulsions for drug delivery
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
FR2683159B1 (fr) * 1991-10-31 1994-02-25 Coletica Procede de fabrication de nanocapsules a paroi a base de proteines reticulees; nanocapsules ainsi obtenues et compositions cosmetiques, pharmaceutiques et alimentaires en comportant application.
WO1994010980A1 (fr) * 1992-11-16 1994-05-26 Corporation Of Mercer University Compositions comprenant des anticorps de neutralisation microencapsules
BR9405798A (pt) * 1993-02-22 1995-12-12 Vivorx Pharmaceuticals Inc Métodos para liberação in vivo de material biológico e composições úteis dos mesmos
US5665382A (en) * 1993-02-22 1997-09-09 Vivorx Pharmaceuticals, Inc. Methods for the preparation of pharmaceutically active agents for in vivo delivery
US5362478A (en) * 1993-03-26 1994-11-08 Vivorx Pharmaceuticals, Inc. Magnetic resonance imaging with fluorocarbons encapsulated in a cross-linked polymeric shell
US5439686A (en) * 1993-02-22 1995-08-08 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor
US5650156A (en) * 1993-02-22 1997-07-22 Vivorx Pharmaceuticals, Inc. Methods for in vivo delivery of nutriceuticals and compositions useful therefor
GB9405593D0 (en) * 1994-03-22 1994-05-11 Zeneca Ltd Pharmaceutical compositions

Also Published As

Publication number Publication date
FR09C0050I1 (fr) 2009-06-11
FR09C0050I2 (fr) 2012-06-22
EP1944019A3 (fr) 2008-07-30
US5916596A (en) 1999-06-29
CN1237901A (zh) 1999-12-08
BRPI9711856B8 (pt) 2021-05-25
PT961612E (pt) 2009-06-17
EP1944019A2 (fr) 2008-07-16
CN1157185C (zh) 2004-07-14
EP0961612A4 (fr) 2005-12-21
DK0961612T4 (da) 2012-10-08
WO1998014174A1 (fr) 1998-04-09
CA2512487C (fr) 2012-05-29
JP5117439B2 (ja) 2013-01-16
CA2267498C (fr) 2007-05-08
DE69739348D1 (de) 2009-05-20
EP0961612A1 (fr) 1999-12-08
JP2001501931A (ja) 2001-02-13
BRPI9711856B1 (pt) 2016-07-12
CA2267498A1 (fr) 1998-04-09
ES2323559T3 (es) 2009-07-20
CN1515244B (zh) 2013-08-07
JP2009185042A (ja) 2009-08-20
DE122009000065I1 (de) 2010-01-07
BR9711856A (pt) 2001-11-06
EP0961612B1 (fr) 2009-04-08
CA2512487A1 (fr) 1998-04-09
AU718753B2 (en) 2000-04-20
EP2286798A1 (fr) 2011-02-23
DK0961612T3 (da) 2009-06-15
NL300417I1 (en) 2009-12-01
EP0961612B2 (fr) 2012-08-01
AU4592997A (en) 1998-04-24
BRPI9715297B8 (pt) 2021-05-25
ATE427739T1 (de) 2009-04-15
BRPI9715297B1 (pt) 2016-07-12
LU91613I2 (fr) 2009-12-07
EP1944019B1 (fr) 2016-09-07
NO328689B1 (no) 2010-04-26
CN1515244A (zh) 2004-07-28
NZ335133A (en) 2000-12-22
ES2323559T5 (es) 2012-12-03
NO991620D0 (no) 1999-04-06
ES2609853T3 (es) 2017-04-24
NO991620L (no) 1999-06-01
JP4837809B2 (ja) 2011-12-14

Similar Documents

Publication Publication Date Title
HK1024866A1 (en) Protein stabilized pharmacologically active agents and their use
MX337149B (es) Nuevas formulaciones de agentes farmacologicos, metodos para su preparacion y metodos para el uso de los mismos.
EP2014286A3 (fr) Particules de epothilone sans cremophor recouvertes de protein pour le traitement du cancer
WO2000071079A3 (fr) Agents a stabilisation proteinique actifs pharmacologiquement; procedes de fabrication et methodes d'utilisation
Kuo et al. Inhibition of human brain malignant glioblastoma cells using carmustine-loaded catanionic solid lipid nanoparticles with surface anti-epithelial growth factor receptor
Zheng et al. Transferrin-conjugated lipid-coated PLGA nanoparticles for targeted delivery of aromatase inhibitor 7α-APTADD to breast cancer cells
AU752466B2 (en) Stabilized ascorbic acid, composition, and method of use
ATE260651T1 (de) Pharmazeutische ciclosporin-formulierung mit verbesserten biopharmazeutischen eigenschaften, erhöhter physikalischer qualität & stabilität sowie verfahren zur herstellung
ATE192333T1 (de) Partikel mit modifizierten physikalisch- chemischen eigenschaften, ihre herstellung und verwendung
BR0016012A (pt) Implante farmacêutico contendo componentes de liberação imediata e de liberação prolongada, além de processo de administração
BG105379A (en) Pharmaceutical compositions for the treatment of acute disorders
ATE350013T1 (de) Nanopartikelzusammensetzungen enthaltend insulin
GB9300875D0 (en) Nanocapsule containing pharmaceutical compositions
AU4457293A (en) Compositions which contain active substances and are in the form of solid particles
ATE124864T1 (de) Die wirkstoffabgabe steuerndes überzugsmaterial für lang wirksame formulierungen.
HK1043548B (zh) 製備包衣藥粒及藥物製劑的方法
HK1038310A1 (en) Compositions and methods for treating intracellular infections.
SG165156A1 (en) Novel formulations of pharmacological agents, methods for the preparation thereof and methods for the use thereof
HUP0100303A2 (hu) Porózus hidroxiapatit részecskék mint gyógyszerhatóanyag hordozók
Kofuji et al. Preparation of chitosan microparticles by water-in-vegetable oil emulsion coalescence technique
NO20011670L (no) Preparat for parenteral administrering av aktive forbindelser
CN115429773B (zh) 一种制备药物纳米结晶制剂的方法
남기영 Antibacterial activity and characterization of tissue conditioner containing silver-chitosan nanocomplex
JPH06336444A (ja) 新規な徐放性フィブリンゲル医薬品組成物
MX9604984A (es) Composiciones farmaceuticas a base de derivados de la clase de los taxanos.

Legal Events

Date Code Title Description
CHRG Changes in the register

Free format text: CORRECTION OF THE NAME OF THE INVENTOR FROM SHIOMO MAGDASSI TO SHLOMO MAGDASSI

PE Patent expired

Effective date: 20170923